IMUNON Secures $3.25M Funding Amid Ovarian Cancer Trials
By ATTN Desk · Editorial oversight: Sean Han
IMUNON INC (NASDAQ: IMNN)
1. Introduction
IMUNON INC (ticker: IMNN; KOSDAQ: 이모논) is a clinical-stage biotechnology company headquartered in Lawrenceville, New Jersey. The company develops DNA-based immunotherapies and vaccines aimed at addressing conditions such as cancer and infectious diseases.
2. Corporate Structure
- Founded: Integration of research, development, and commercialization
- Headquarters: Lawrenceville, New Jersey, U.S.
- Employee Count: 11–50
- Leadership Experience: Senior executives with over 50 combined years in research, innovation, and capital management
- Platform Technologies:
- TheraPlas®: Gene-based delivery of cytokines and therapeutic proteins for solid tumors
- PlaCCine®: Nucleic acid vaccines for infectious diseases and cancer
3. Recent Developments and News
- 2025-05-20: Filed Form 8-K (Item 3.01) referencing a material agreement without further public detail.
- 2025-05-22:
- Filed Form 8-K (Item 8.01) to report “other events” with no additional disclosures.
- Submitted a Registration Withdrawal Request for Form S-1 (File No. 333-286403); no securities were sold; fees to be credited for future offerings.
- 2025-05-23: Announced a private placement under Nasdaq rules:
- Shares Issued: 7,222,223 common stock (or pre-funded warrants) at $0.45 per share
- Warrants Issued: 14,444,446 short-term warrants at a $0.45 per share exercise price
- Gross Proceeds: $3.25 million upfront; up to $6.5 million upon full warrant exercise
- Use of Proceeds: Intended for working capital and general corporate purposes
- Placement Agent: H.C. Wainwright & Co.; Financial Advisor: Brookline Capital Markets
- 2025-04-25‒04-30: Participated in AACR Annual Meeting; discussed TheraPlas® research and engaged with oncology researchers.
- 2025-05-30‒06-03: Oral presentation scheduled at the ASCO Annual Meeting on Phase 2 OVATION 2 data related to advanced ovarian cancer.
- Phase 3 OVATION 3: Initiated the first clinical site for newly diagnosed advanced ovarian cancer; participant enrollment is currently underway.
- Q1 2025 Financial Results Call: Provided updates on clinical progress including the Phase 3 development of the lead ovarian cancer candidate.
4. Financial and Strategic Analysis
| Metric | Value |
|---|---|
| Share Price (2025-05-26 Close) | $1.16 |
| One-Day Change | +179.18% |
| Volume (2025-05-26) | 413,579,632 |
| 52-Week Range | $0.37 – $3.65 |
| Market Cap (Intraday) | $16.96 million |
| Average Volume | 7,110,613 |
| Cash (MRQ) | $2.87 million |
| Total Debt/Equity (MRQ) | 223.01% |
| Net Income (TTM) | –$17.79 million |
| Diluted EPS (TTM) | –1.38 |
| Levered Free Cash Flow (TTM) | –$9.03 million |
| Beta (5Y Monthly) | 1.75 |
| 1-Year Target Estimate | $9.75 |
- Capital Raising: The $3.25 million placement provides liquidity; full warrant exercise could add $6.5 million.
- Cash Runway: $2.87 million on hand as of the latest quarter; negative free cash flow indicates reliance on further fundraising.
- Valuation: Market cap of $16.96 million; negative earnings reported; high price volatility (beta 1.75).
- Pipeline: Two key pre-clinical candidates (IMNN-201 for melanoma; IP-Y personalized neoepitope vaccines) target markets estimated in the billions.
5. Market Position and Industry Context
- Sector: Biotechnology (Immunology & DNA-based therapies)
- Competitive Landscape: Companies developing non-viral gene therapies, mRNA vaccines, checkpoint inhibitors, and personalized cancer vaccines.
- Addressable Markets:
- Advanced ovarian cancer: approximately 54 new U.S. diagnoses per day (Ovarian Cancer Research Alliance)
- Melanoma and other solid tumors
- Emerging infectious diseases requiring new vaccine platforms
- Partnerships: Collaborations with leading research institutions and potential future licensing or co-development agreements to broaden clinical programs.
tl;dr
- On 2025-05-23, IMUNON raised $3.25 million via a Nasdaq-priced private placement; closing expected by 2025-05-27.
- Phase 3 OVATION 3 trial for newly diagnosed advanced ovarian cancer is underway; ASCO presentation scheduled for 2025-05-30‒06-03.
- Cash balance of $2.87 million (MRQ), negative free cash flow; full warrant exercise could provide an additional $6.5 million.
- Pipeline includes two pre-clinical DNA-based candidates with combined addressable markets estimated in the billions.
- 1-year price target of $9.75 set by analysts; market cap reported at $16.96 million as of 2025-05-26.